Videos

Richard Nowak, MD, MS, reviews 52-week efficacy data from the MINT trial, highlighting durable improvements in MG-ADL and QMG scores and what the evolving treatment-placebo separation means for long-term disease control.

Katherine B. Peters, MD, PhD, reviews the exploratory seizure analysis from the phase 3 INDIGO trial (NCT04164901), discussing the numerical reduction in seizure burden with vorasidenib, the limitations of patient-reported seizure data, and how clinicians should interpret these findings in practice.

The discussion explores the evolving management of myasthenia gravis (MG), focusing on treatment selection, sequencing, and strategies for switching therapies in clinical practice. The expert faculty highlight how the expanding range of targeted therapies, including FcRn inhibitors, complement inhibitors, and B-cell–depleting agents, has enabled more individualized, patient-centered care, balancing short-term symptom control with long-term disease management. The panelists emphasize a shift toward earlier, proactive optimization of therapy to improve long-term outcomes and reduce disease burden in patients with MG.

In honor of Stroke Awareness Month, the medical director for telestroke at Allegheny Health Network discussed how evolving imaging modalities may be reshaping stroke care. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending May 9th, 2026. [WATCH TIME: 5 minutes]

Explore evidence-based CIDP therapy: IVIG dosing from the ICE trial, steroid tradeoffs, and how clinicians tailor treatment to comorbidities.

Richard Nowak, MD, MS, outlines the design of the phase 3 MINT trial, highlighting its patient population, forced steroid taper, and the rationale for extending evaluation to a 52-week randomized control period.

CIDP management tackles fatigue, pain, mood, and rehab—plus the hunt for early biomarkers and more effective therapies.

Katherine B. Peters, MD, PhD, reviews the phase 3 INDIGO trial (NCT04164901), highlighting its patient population, significant progression-free survival benefit, and the impact of vorasidenib on delaying disease progression and need for further intervention.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the FDA's decision, and also discussed the evolving SMA treatment landscape in general terms. [WATCH TIME: 11 minutes]

The director of the Center for Neurological Restoration at Cleveland Clinic commented on tavapadon’s D1-selective mechanism, clinical development, and potential role in treating Parkinson disease across stages. [WATCH TIME: 4 minutes]

The director of the Neuromuscular Division at the Medical University of South Carolina shared post hoc CHAMPION-MG trial findings at MDA 2026, suggesting ravulizumab may enable corticosteroid reduction while maintaining or improving clinical outcomes. [WATCH TIME: 4 minutes]

Following his symposium at the 2026 AAN Annual Meeting, science educator Bill Nye discussed his connection to Friedreich ataxia, emphasizing the importance of awareness, early diagnosis, and effective communication between clinicians and patients. [WATCH TIME: 4 minutes]

The associate chief quality officer at Nationwide Children’s Hospital discussed how AI-driven research initiatives within PERC are helping identify missed epilepsy diagnoses and improve care pathways in pediatric populations. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending May 2nd, 2026. [WATCH TIME: 5 minutes]

In this episode, "Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants," the panelists in neurology and neuromuscular medicine explore the practical utility of the 2021 EAN/PNS CIDP guidelines and the considerable complexity introduced by disease variants. The discussion opens with a question about monophasic CIDP, with one expert noting that 20–30% of patients can achieve drug-free remission after initial treatment, suggesting a subset of patients experience a self-limiting course that nonetheless meets the diagnostic threshold of progression or relapse beyond two months.

Richard Nowak, MD, MS, outlines the biologic rationale for CD19-targeted therapy in generalized myasthenia gravis, highlighting how inebilizumab differs from CD20-directed approaches and why broader B-cell depletion may offer clinical advantages.

The clinical professor of adult neurology at Stanford University discussed data he presented at AAN's 2026 Meeting [WATCH TIME: 4 minutes]

Welcome back to another NeurologyLive Peer Exchange series. The panel opens with a discussion of CIDP prevalence, noting that estimates vary depending on the diagnostic criteria used. A strict case definition from a New South Wales population study places prevalence at approximately 1 per 100,000, while a more clinically based study from Olmsted County suggests a higher figure of around 1 in 10,000. One expert contextualizes this further, estimating that roughly 40,000–50,000 patients in the U.S. are affected, and that CIDP accounts for approximately 20% of patients presenting to peripheral neuropathy centers with initially unrecognized neuropathy. The panel characterizes CIDP as rare but not ultra-rare.

Katherine B. Peters, MD, PhD, breaks down how IDH mutations drive 2-hydroxyglutarate production and how this process contributes to both tumor growth and seizure activity in glioma.

Katherine B. Peters, MD, PhD, outlines how seizures shape the lived experience of patients with grade 2 IDH-mutant glioma, highlighting their impact on independence, employment, and long-term quality of life.

The associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania discussed pivotal data on zilganersen, highlighting its efficacy, safety, and potential as the first disease-modifying therapy for Alexander disease.

Duchenne trials accelerate with next-gen gene therapy, muscle-protecting drugs, and improved exon-skipping approaches—aiming for safer, longer-lasting benefits and easier dosing.

Clinicians tailor Duchenne treatment over time, balancing steroid benefits, side effects, ambulation changes, and required monitoring for newer therapies and families.

The founder and president of the Indian Federation of Neurorehabilitation highlighted emerging technologies and evolving therapeutic strategies shaping the future of neurorehabilitation. [WATCH TIME: 5 minutes]

The deputy director at Association of Movement Disorder Advanced Practice Providers (AMDAPP) recapped key themes in movement disorders presented at the 2026 AMDAPP conference. [WATCH TIME: 5 minutes]

The assistant professor in the Department of Chemistry and Biochemistry at University of Nevada, Las Vegas reflected on receiving the first MDA Research Momentum Award at the 2026 MDA Conference. [WATCH TIME: 2 minutes]

The director of the autoimmune neurology program at the University of Colorado discussed data she presented at AAN's 2026 Meeting [WATCH TIME: 5 minutes]

Neurology News Network for the week ending April 25th, 2026. [WATCH TIME: 5 minutes]

Mitzi Joi Williams, MD, and Carol Coleman break down insurance basics, prior authorizations, and practical strategies to help patients navigate cost and access challenges at the start of the year.